Aaron Wealth Advisors’s Avidity Biosciences RNAM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-8,562
| Closed | -$618K | – | 752 |
|
|
2025
Q4 | $618K | Buy |
8,562
+22
| +0.3% | +$1.42K | 0.03% | 377 |
|
|
2025
Q3 | $372K | Buy |
8,540
+1,206
| +16% | +$48.8K | 0.02% | 478 |
|
|
2025
Q2 | $208K | Buy |
7,334
+129
| +2% | +$3.85K | 0.02% | 466 |
|
|
2025
Q1 | $213K | Sell |
7,205
-897
| -11% | -$27.9K | 0.02% | 419 |
|
|
2024
Q4 | $236K | Buy |
8,102
+504
| +7% | +$21.1K | 0.03% | 384 |
|
|
2024
Q3 | $349K | Buy |
+7,598
| New | +$330K | 0.04% | 265 |
|
|
2024
Q1 | – | Sell |
-134,242
| Closed | -$1.21M | – | 313 |
|
|
2023
Q4 | $1.21M | Buy |
134,242
+828
| +0.6% | +$5.54K | 0.2% | 66 |
|
|
2023
Q3 | $851K | Sell |
133,414
-3,494
| -3% | -$30.1K | 0.11% | 96 |
|
|
2023
Q2 | $1.52M | Sell |
136,908
-1,512
| -1% | -$19K | 0.2% | 76 |
|
|
2023
Q1 | $2.12M | Hold |
138,420
| – | – | 0.29% | 55 |
|
|
2022
Q4 | $3.07M | Sell |
138,420
-77,330
| -36% | -$1.15M | 0.45% | 45 |
|
|
2022
Q3 | $3.52M | Hold |
215,750
| – | – | 0.65% | 36 |
|
|
2022
Q2 | $3.13M | Sell |
215,750
-3,769,152
| -95% | -$56.1M | 0.79% | 30 |
|
|
2022
Q1 | $216M | Buy |
3,984,902
+3,769,152
| +1,747% | +$64M | 2.99% | 7 |
|
|
2021
Q4 | $5.13M | Sell |
215,750
-13,845
| -6% | -$331K | 1.43% | 18 |
|
|
2021
Q3 | $5.65M | Hold |
229,595
| – | – | 1.59% | 15 |
|
|
2021
Q2 | $5.67M | Sell |
229,595
-180,586
| -44% | -$4.2M | 1.87% | 13 |
|
|
2021
Q1 | $8.95M | Sell |
410,181
-114,058
| -22% | -$2.79M | 3.28% | 8 |
|
|
2020
Q4 | $13.4M | Buy |
+524,239
| New | +$15.3M | 4.9% | 3 |
|
Other funds holding RNAM
Aaron Wealth Advisors's RNAM Position: Q1 2026 in Review
Aaron Wealth Advisors sold out of Avidity Biosciences (RNAM) in Q1 2026, closing a stake of 8,562 shares — an estimated $618K sold.
Aaron Wealth Advisors first reported a position in RNAM in Q4 2020 and held it in 19 quarters. The position peaked at $216M in Q1 2022. 1 fund tracked by Wall St. Rank holds RNAM as of Q1 2026.
- Aaron Wealth Advisors reported no remaining Avidity Biosciences position as of Q1 2026 after selling out during the quarter.
- Aaron Wealth Advisors sold 8,562 Avidity Biosciences shares in Q1 2026, an estimated $618K.
- Aaron Wealth Advisors first reported a position in Avidity Biosciences in Q4 2020 and held it in 19 quarters.
- Aaron Wealth Advisors's Avidity Biosciences position peaked at $216M in Q1 2022.
- 1 fund tracked by Wall St. Rank held Avidity Biosciences as of Q1 2026.
Based on Aaron Wealth Advisors's 13F filing for Q1 2026, filed 21 Apr 2026.